SCHEMBL7424636

SCHEMBL7424636

Cc1n[nH]cc1CO

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2918126 0.82
SCHEMBL8849656 0.80 KCNH2 (0.35)
SCHEMBL4054528 0.76
SCHEMBL4704957 0.76
SCHEMBL932426 0.76
Hydrochloric Acid SCHEMBL16585011 0.74
Hydrochloric Acid SCHEMBL20299016 0.74
SCHEMBL21310404 0.74
SCHEMBL25409861 0.74 GABRR1 (0.39)
SCHEMBL11323708 0.73

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250026759-A1 TETRAHYDROQUINAZOLINE DERIVATIVES AS SELECTIVE CYTOTOXIC AGENTS MERCK SHARP & DOHME LLC (US) 2025-01-23 US disclosed
WO-2023169226-A1 SUBSTITUTED TRICYCLIC COMPOUNDS AS PARP INHIBITORS AND THE USE THEREOF Impact Therapeutics (Shanghai), Inc (CN) 2023-09-14 WO disclosed
US-20230219938-A1 COMPOUNDS AND THEIR METHODS OF USE PRAXIS PREC MEDICINES INC (US) 2023-07-13 US disclosed
US-20230219938-A1 COMPOUNDS AND THEIR METHODS OF USE PRAXIS PREC MEDICINES INC (US) 2023-07-13 US disclosed
US-20230219938-A1 COMPOUNDS AND THEIR METHODS OF USE PRAXIS PREC MEDICINES INC (US) 2023-07-13 US disclosed
US-RE49517-E1 Pyrazoles Janssen Pharmaceuticals, Inc. (US) 2023-05-02 US disclosed
US-RE49517-E1 Pyrazoles Janssen Pharmaceuticals, Inc. (US) 2023-05-02 US disclosed
US-11492345-B2 Compounds and their methods of use PRAXIS PRECISION MEDICINES, INC. (US) 2022-11-08 US disclosed
US-20200247793-A1 COMPOUNDS AND THEIR METHODS OF USE PRAXIS PRECISION MEDICINES, INC. (US) 2020-08-06 US disclosed
US-20200247793-A1 COMPOUNDS AND THEIR METHODS OF USE PRAXIS PRECISION MEDICINES, INC. (US) 2020-08-06 US disclosed
WO-2018144620-A1 ANTI-FIBROTIC COMPOUNDS SHIRE HUMAN GENETIC THERAPIES, INC. (US) 2018-08-09 WO disclosed
US-20170275254-A1 PYRAZOLES JANSSEN PHARMACEUTICALS INC (US) 2017-09-28 US disclosed
US-20170275254-A1 PYRAZOLES JANSSEN PHARMACEUTICALS INC (US) 2017-09-28 US disclosed
WO-2016025918-A1 PYRAZOLES Janssen Pharmaceuticals, Inc. (US) 2016-02-18 WO disclosed
WO-2007145349-A2 SUBSTITUTED PYRROLE DERIVATIVES TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2007-12-21 WO disclosed
EP-0986562-A1 SUBSTITUTED 1,2,4-TRIAZOLO 3,4-A]PHTHALAZINE DERIVATIVES AS GABA ALPHA 5 LIGANDS MERCK SHARP &amp; DOHME LTD. (GB) 2000-03-22 EP disclosed
WO-1998050385-A1 SUBSTITUTED 1,2,4-TRIAZOLO[3,4-a]PHTHALAZINE DERIVATIVES AS GABA ALPHA 5 LIGANDS MERCK SHARP & DOHME LIMITED (GB) 1998-11-12 WO disclosed
WO-1997041128-A1 3-PYRAZOLIOMETHYLCEPHEM COMPOUNDS AS ANTIMICROBIAL AGENTS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1997-11-06 WO disclosed
EP-0667868-A1 NEW CEPHEM COMPOUNDS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1995-08-23 EP disclosed
EP-0223246-A2 New cephem compounds and processes for preparation thereof FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1987-05-27 EP disclosed